CSTL vs ETON: fair value comparison
Castle Biosciences, Inc. and Eton Pharmaceuticals, Inc. · Updated 2026-10-19
CSTL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. ETON is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, CSTL currently ranks higher by quality score.
| CSTL | ETON | |
|---|---|---|
| Verdict | No estimate yet | Awaiting full valuation |
| Last price | $31.96 | $50.31 |
| 12-month range | $18.15–$43.04 | $14.35–$64.43 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #50 of 301 Healthcare | #51 of 301 Healthcare |
| Quality grade | B | B |
| Leverage | Low | Moderate |
| Margin trend | Contracting | Contracting |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: CSTL fair value analysis · ETON fair value analysis